Anhui Wanbang Pharmaceutical Technology Co Ltd

Anhui Wanbang Pharmaceutical Technology Co Ltd maintains a strong liquidity position with a current ratio of 20.79, indicating a high ability to meet short-term obligations. However, the company reported negative operating cash flow of -7.92 million CNY, which contrasts with a positive free cash flow of 10.65 million CNY, suggesting that capital expenditures are being offset by other cash inflows. The company's capital structure is largely equity-driven, with total liabilities of 87.13 million CNY and total equity of 1.52 billion CNY, resulting in a debt-to-equity ratio of 0. Profitability metrics show a return on equity (ROE) of 2.4% and a return on assets (ROA) of 2.27%, which are below the typical thresholds for high-growth biotechnology firms. The company's gross profit margin is 25.05% (68.67 million CNY gross profit on 274.18 million CNY revenue), and its operating margin is 14.95% (40.98 million CNY operating income on 274.18 million CNY revenue). These figures suggest moderate profitability relative to industry expectations for diagnostic firms. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of segmentation data limits visibility into regional exposure and potential market concentration risks. The absence of detailed segment reporting also obscures the relative performance of different product lines or geographic regions. Looking ahead, the company's revenue growth trajectory is unclear due to the lack of multi-year historical data. The current fiscal year outlook does not provide specific revenue growth targets, and no forward-looking guidance is available for the next fiscal year. The company's capital expenditure of -19.22 million CNY indicates a net outflow for investments, which may support future growth but could also pressure short-term liquidity. Risk factors include a medium liquidity risk due to the negative net cash position after accounting for total debt. The company's dilution risk is assessed as low, with no near-term pressure from share issuance or convertible instruments. However, the absence of detailed dilution sources in the input data limits the ability to fully assess potential equity dilution risks. Recent events and filings do not provide specific details on material developments, such as new product launches, regulatory approvals, or strategic partnerships. The lack of recent transcript data or 10-K filings limits the ability to assess management commentary or strategic direction.